2 Proven Procedures. 1 Streamlined Case. 1 Patient Recovery.
Concomitant FARAWATCH™ procedures using the FARAPULSE Pulsed Field Ablation (PFA) Platform and WATCHMAN FLX Pro Left Atrial Appendage Closure (LAAC) Device enable physicians to effectively treat AFib patients while providing stroke protection in one streamlined case and recovery process.
Together, we can transform AFib care.
Why concomitant FARAPULSE PFA and WATCHMAN LAAC?
- Streamlined approach that benefits patients, increases operational efficiency, and reduces resource burden
- Patients and physicians can feel confident they are addressing both the symptoms of AFib while reducing the risk of stroke and bleeding at the same time
- The most widely used technologies in PFA and LAAC, the FARAPULSE Platform and the WATCHMAN FLX Pro LAAC Device lead the way in enabling safe and efficient AFib treatment and stroke protection
600,000 WATCHMAN patients have been treated globally
Clinically Proven
The FARAPULSE Platform and WATCHMAN LAAC Device lead the way in clinical evidence for their therapy offerings:
The FARAPULSE Platform has built the largest and most comprehensive clinical evidence base in pulsed field ablation, with unmatched volume in peer-reviewed studies, registry participation, and patient outcomes across pivotal trials and real-world registries.
The OPTION Clinical Trial3,5, a breakthrough study in AFib treatment, is the first randomized, head-to-head study comparing WATCHMAN to OAC (95% DOACs) after cardiac ablation*.
*Thermal AFib ablation only.
FARAWATCH Case Study
Watch Dr. Wassim Jawad perform concomitant AFib ablation and LAAC procedures using the FARAWAVE™ NAV PFA Catheter and WATCHMAN FLX™ Pro Device, demonstrating effective AFib treatment and stroke protection in one streamlined case.
The Leaders in AFib Treatment and Stroke Protection
Insights
MedAxiom White Papers
EDUCARE
This content is housed on EDUCARE, our online education platform. An account is required; follow these instructions to set up your free account.
† MAE data reflect outcomes from a real-world registry. SAE rate of 2.1% observed in the ADVENT Pivotal Trial evaluating the FARAPULSE™ Pulsed Field Ablation System. Source: Reddy, Vivek Y., et al. “Pulsed field or conventional thermal ablation for paroxysmal atrial fibrillation.” New England Journal of Medicine 389.18 (2023): 1660-1671.
References
- Ekanem E, Reddy VY, et al. Multi-National Survey on the Safety of the post-approval clinical use of Pulsed Field Ablation in 17,000 + patients (MANI FEST 17K)
*Defined as the occurrence of death, stroke, esophageal fistula or dysmotility, pulmonary vein stenosis, persistent phrenic nerve injury, pericardial tamponade, vascular complication, coronary artery spasm, hemolysis, or thrombosis - Piccini et al. Poster Presentation. HRS 2 025.
*Defined as the occurrence of all-cause death, ischemic stroke, systemic embolism, or device or procedure related events requiring open cardiac surgery or major endovascular intervention between device implantation and seven days or hospital discharge (whichever is later). Includes device or procedure related events requiring open cardiac surgery or major endovascular intervention such as pseudoaneurysm repair, AV fistula repair, or other major endovascular repair. - Wazni O, et al. New England Journal of Medicine, November 2024 . Primary Efficacy: Stroke, mortality, systemic embolism. Primary Safety: Non-procedural ISTH major and clinically-relevant non-major bleeding
- Eckart R, et al. Heart Rhythm O2. 2025;In-Press:1-8. doi:10.1016/j.hroo.2025.07.014
- Saliba W, et al. Heart Rhythm Journal, May 2025.